News

xFOREST Therapeutics Announces Drug Discovery Collaboration with Daiichi Sankyo to Target RNA Structures in Multiple Diseases

xFOREST Therapeutics (Headquarter: Kamigyo-ku, Kyoto, Japan; President and CEO: Shunichi Kashida; hereinafter, xFOREST) announced today that it has reached an agreement with Daiichi Sankyo Company, Limited (Headquarter: Chuo-ku, Tokyo, Japan; hereinafter, Daiichi Sankyo）on a drug discovery collaboration to target RNA structures in multiple diseases.

Under the agreement, xFOREST will provide its proprietary FOREST technologies, a suite of large-scale parallel analysis platforms, to promote systematic small molecule drug discovery research targeting RNA structures. Daiichi Sankyo will have exclusive rights to develop and commercialize RNA-targeted small molecules identified from the collaboration.